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b-Synthase Subunits in Homocystinuria
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Jan P. Kraus,2 and Viktor Kozˇich1,2
1Institute of Inherited Metabolic Disease, Charles University First Faculty of Medicine, Prague; and 2Department of Pediatrics, University of
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During the past 20 years, cystathionine b-synthase (CBS) deficiency has been detected in the former Czechoslovakia
with a calculated frequency of 1:349,000. The clinical manifestation was typical of homocystinuria, and about
half of the 21 patients were not responsive to pyridoxine. Twelve distinct mutations were detected in 30 independent
homocystinuric alleles. One half of the alleles carried either the c.833 TrC or the IVS1152ArC mutation; the
remaining alleles contained private mutations. The abundance of five mutant mRNAs with premature stop codons
was analyzed by PCR-RFLP. Two mRNAs, c.828_931ins104 (IVS7+1GrA) and c.1226 GrA, were severely reduced
in the cytoplasm as a result of nonsense-mediated decay. In contrast, the other three mRNAs—c.19_20insC,
c.28_29delG, and c.210_235del26 (IVS151GrC)—were stable. Native western blot analysis of 14 mutant fibro-
blast lines showed a paucity of CBS antigen, which was detectable only in aggregates. Five mutations—A114V
(c.341CrT), A155T (c.463GrA), E176K (c.526GrA), I278T (c.833TrC), andW409_G453del (IVS1152ArC)—
were expressed in Escherichia coli. All five mutant proteins formed substantially more aggregates than did the
wild-type CBS, and no aggregates contained heme. These data suggest that abnormal folding, impaired heme
binding, and aggregation of mutant CBS polypeptides may be common pathogenic mechanisms in CBS deficiency.
Homocystinuria due to cystathionine b-synthase (CBS)
deficiency (MIM 236200) is an autosomal recessive trait
that phenotypically resembles Marfan syndrome. Unless
diagnosed by neonatal screening and treated appropri-
ately, homocystinuria manifests, usually in infancy and
childhood, with disturbances in connective tissue, vas-
culature, and the central nervous system. Since the first
identification of mutations in the CBS mRNA (Kozich
and Kraus 1992), 1350 homocystinuric alleles with1100
distinct mutations have been reported worldwide (Kraus
et al. 1999; authors’ Web site). Some of these mutant
alleles are present in all populations (e.g., the c.833 TrC
mutation conferring pyridoxine responsiveness), but
others are confined to specific populations. The vast ma-
jority of homocystinuric alleles all over the world carry
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private mutations (Kraus et al. 1999). Although several
mutations have been expressed in Escherichia coli (Ko-
zich and Kraus 1992; de Franchis et al. 1994; Dawson
et al. 1997; Kluijtmans et al. 1999) or yeast (Shan and
Kruger 1998), detailed reports on pathogenicity of in-
dividual mutations in homocystinuria are lacking. In the
present report, we describe the mutation analysis of a
group of Slavic patients with homocystinuria, with a
focus on the consequences of mutations at the RNA and
protein levels.
CBS deficiency is the most common disorder of sulfur
amino acid metabolism, with an incidence of 1:57,000–
1:1,000,000 (Mudd et al. 2001). In the region of the
former Czechoslovakia, homocystinuria has been ascer-
tained only by the selective biochemical screening. With
a correction for diagnosis delay, the calculated frequency
of detection of homocystinuria during the past 20 years
is 1:349,000 (95% confidence interval 1:208,000–1:
641,000). The clinical phenotype of all 21 Czech and
Slovak patients with CBS deficiency was without any
peculiar findings and corresponded to the previous re-
port of a series of 629 patients (Mudd et al. 1985). The
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Figure 1 The relative abundance of mRNAs that carry premature termination codon. Top, Analysis of genomic DNA. Restriction-site
analysis shows fragments of 122 bp, in the case of a T allele in position 699, and of 92 bp, if the C allele is present. The undigested 304-bp
PCR products that contain a control RsaI are not shown. Lanes 1 and 9, Molecular-weight markers. Lane 2, Patient 4 [IVS71GrA; c.699C]/
[IVS112ArC; and c.699T]. Lane 3, Patient 6 [c.1226GrA; c.699T ]/[IVS112ArC; c.699C]. Lane 4, Patient 9 [c.19_20insC; c.699C]/
[IVS112ArC; c.699T]. Lane 5, Patient 10 [IVS11GrC; c.699C]/[c.28_29delG; c.699T]. Lane 6,Wild-type control c.699C/C. Lane 7,Wild-
type control c.699T/T. Lane 8, Wild-type control c.699C/T. Bottom, RT-PCR/RFLP analysis of total fibroblast RNA. The presence of T and C
in position 699 is signified by the 280-bp and 248-bp fragments, respectively. The uncut PCR products of 392 bp that contain a control RsaI
are not shown. The lanes contain samples identical to those in top panel. The absence of a fragment signifying the C allele in lane 2 demonstrates
that the mRNA that carries the c.828_931ins104 (IVS71GrA) is not present in the RNA preparation. Similarly, the absence of the T allele
in lane 3 shows the virtual absence of the mRNA molecules carrying the c.1226GrA (W409X).
number of pyridoxine responders equaled that of non-
responders, which is similar to that in other populations
in Europe (Mudd et al. 1985).
We analyzed the underlying molecular causes of CBS
deficiency in all cases where fibroblasts and/or blood
were available. Mutations were detected by sequencing
both the cDNA (Kozich and Kraus 1992) and genomic
DNA (see Primers and ConditionsWeb site). In addition,
all mutations were verified in genomic DNA by use of
independent PCR-RFLP assays. Among the Czech and
Slovak patients with CBS deficiency, we detected 12 dis-
tinct mutant alleles (see table 1). About one-half of the
30 independent homocystinuric alleles carried private
mutations, while the other half was represented equally
by alleles that bear the c.833TrC or the IVS112ArC
mutation.
The high prevalence of the c.833TrC allele, which
confers pyridoxine responsiveness, was not surprising,
because this transition is clearly the most prevalent path-
ogenic CBS mutation in whites (Kraus et al. 1999). On
the other hand, the IVS112ArC mutation seems to be
present only in central Europe; it has been observed in
patients of East German, Austrian, and Turkish origin
(Koch et al. 1994), but it has never been detected in
numerous homocystinuric alleles of people fromwestern
and southern Europe.
Five mRNAs predicted premature termination co-
dons at various exons: c.19_20insC predicted a pre-
mature termination codon in exon 1; c.28_29delG
and c.210_235del26 (IVS11GrC) in exon 2; 828_
931ins104 (IVS71GrA) in exon 8; and c.1226GrA
(W409X) in exon 12. Given that the naturally occurring
stop codon in the wild-type CBS mRNA is located in
exon 16, mRNAs that carry any of these five mutations
would presumably be subject to nonsense-mediated de-
cay (Nagy and Maquat 1998; Frischmeyer and Dietz
1999). Because all patients with these mutations were
heterozygous for a neutral synonymous mutation—
c.699CrT (Y233Y)—we analyzed the abundance of
CBS mRNAs carrying premature stop codon, using a
simple PCR-RFLP method (see fig. 1). Both genomic
DNA and cDNA were amplified by PCR, and the PCR
products were digested with RsaI and electrophoresed
on 4%Metaphor agarose, as described elsewhere (Kraus
et al. 1993).
Surprisingly, only two of five mutants were severely
depleted below the detection limit of the RT-PCR–RFLP
method (fig. 1, bottom). The loss of heterozygosity for
the c.699CrT synonymous mutation suggests that
the mRNAs carrying the mutations 828_931ins104
(IVS71GrA) or c.1226GrA (W409X) are degraded
by nonsense-mediated decay. Our result may explain
why the c.1226GrA (W409X)mutation was pathogenic
in patients 6 and 18 of the series reported here, whereas
the protein that is truncated at or near W409 and that
is expressed in bacteria or yeast has an increased activity
(Kery et al. 1997; Shan and Kruger 1998). We postulate
that the pathogenicity of the c.1226GrA (W409X) mu-
tation in humans results from a nonsense-mediated de-
cay of the mutant mRNA before translation.
In contrast, the mRNA molecules that bear the mu-
tations c.19_20insC, c.28_29delG, and c.210_235del26
(IVS11GrC) were abundant and easily detectable
by the RT-PCR method, suggesting that their stability
was not severely compromised. The c.19_20insC mu-
tation is an extra C inserted into a sequence of six
Reports 1509
Figure 2 Western blot analysis of fibroblast extracts (native PAGE). The normally assembled tetramer is present only in control fibroblasts
(10 mg of protein per lane) and is not detectable in any of the mutant cell lines (100 mg of protein per lane). Lane numbers correspond to
patient numbers in table 2. Lanes 1, 2, 3, 4, 6 7, 9, 10, and 11 show results in patients who were not responsive to pyridoxine. Lane N shows
results in a negative sample, mutant cell line 599 devoid of any CBS antigen (Skovby et al. 1984); lanes 13, 17, 19, and 20 show results in
patients who were fully or partially responsive to pyridoxine. Lane C1 shows results in control fibroblasts 2047 with the sample frozen and
thawed twice; lane C2 shows results in control fibroblasts 2047 analyzed in a separate experiment. The extract for lane C2 was prepared
immediately before loading, with addition of b-mercaptoethanol and protease inhibitors.
Figure 3 Western blot analysis of mutants expressed in E. coli
(SDS-PAGE). Lanes (50 mg of total protein each): A114V (c.341CrT);
A155T (c.463GrA); E176K (c.526GrA); I278T (c.833TrC); del ex
12 (W409_G453del [IVS112ArC]) mutants;WT indicateswild-type
pHCS3; NC indicates negative control (E. coli transformed with pKK
388.1 plasmid without the human CBS insert).
cytidines, and it probably originates from a slipped
mispairing at the replication fork (Cooper et al.
1995). The c.19_20insC mutation leads to a frameshift
with a premature termination codon in exon 1 and pre-
dicts instability of the mRNA resulting from nonsense-
mediated decay. Patients who are homozygous for this
mutation would be expected to be true null mutants,
with no mRNA and no translated CBS protein. How-
ever, fibroblasts derived from patient 3, who is homo-
zygous for the c.19_20insC mutation, contained an ap-
preciable amount of CBS mRNA, which allowed
mutation analysis (data not shown). In addition, the fi-
broblasts of patient 3 contained residual CBS activity
that was 2.5% of control values (see table 2), although
the native western blot analysis did not detect any nor-
mal CBS tetramers (fig. 2). It is conceivable that (1) RNA
polymerase slippage may have produced some mRNA
molecules carrying six cytidines, instead of the seven
cytidines contained in the genomic DNA, and (2) trans-
lation of these wild-type mRNA molecules yielded small
amounts of normal CBS polypeptide. To test whether
RNA polymerase slippage may have been operational,
we amplified and cloned the 5′ portion of mRNA, using
RT-PCR with total RNA preparations. Among the 100
colonies screened for the presence of the c.19_20insC,
we observed 1 wild-type clone (which was devoid of
mutation) and 99 mutant clones. We examined whether
this result was caused by the in vitro infidelity of DNA
polymerase during PCR. We subsequently amplified, by
PCR, and cloned a part of exon 1, using genomic DNA
of this patient; all 100 tested colonies contained only
the c.19_20insC, suggesting that PCR did not artificially
produce the wild-type allele in the course of cDNA anal-
ysis. However, it is also possible that the observed re-
sidual activity may have originated from mosaicism for
cells carrying both six and seven cytidines, or from trans-
lational frameshifting (Horsburgh et al. 1996; Fara-
baugh 2000). Taken together, our data suggest that RNA
polymerase slippage and other mechanisms may func-
tion in vivo and thus modify the primary genetic defect
in patients with the c.19_20insC mutation.
Frameshifting of the c.28_29delG and c.210_
235del26 (IVS11GrC) alleles predicts a premature
termination of translation in exon 2 at amino acid res-
idues 81 and 94, respectively. Again, the positions of the
premature stop codons are consistent with the rules of
nonsense-mediated decay. However, the mRNAs carry-
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Figure 4 Oligomeric status and heme content of CBS mutants expressed in E. coli (native PAGE). Left, Immunodetection. The correctly
assembled tetramers, marked as “4-mer,” are present in the wild-type lane and, in greatly diminished amounts, in A114V (c.341CrT) and
E176K (c.526GrA) mutants. Aggregates of low mobility are present in all extracts as a smear. Lanes (each containing 50 mg of total protein)
are as follows: A114V (c.341CrT); A155T (c.463GrA); E176K (c.526GrA); I278T (c.833TrC); W409_G453del (IVS112ArC) mutants
cloned in pHCS3; WT50%, wild type pHCS3, 25 mg of total protein per lane; WT, wild type pHCS3, 50 mg; NC, negative control, E. coli
transformed with pKK 388.1 plasmid without human CBS insert. Right, Heme staining. Non-CBS staining reaction of E. coli heme proteins
was observed in all samples, including the negative control (top and bottom bands in all lanes). The protein loading is the same as in the panel
at left. Heme bound to CBS is detectable only in the tetramers, both in the wild type and in the A114V (c.341CrT) mutant, but it is absent
in the aggregates.
ing these mutations are clearly abundant in total RNA
preparations and are easily detectable by RT-PCR. Be-
cause both these mutant alleles carry a downstream me-
thionine (either a newly formed one at position 10, in
the case of mutation c.28_29delG, or a naturally oc-
curring one at position 89, in the case of mutation
c.210_235del26 [IVS11GrC]), we propose that the
mutant mRNA molecules may have been stabilized by
translation reinitiation (Zhang and Maquat 1997). Un-
fortunately, the sensitivity of the western blotting for
CBS and the specificity of the in vitro translation assay
are insufficient to test this hypothesis.
The CBS deficiency was confirmed in cultured skin
fibroblasts of 16 patients, in whom a range (0%–2.5%
of control values) of the residual activity was present
(see table 2). To determine whether the decreased CBS
activity originates from an impaired catalytic activity or
from the depletion of CBS polypeptides, we performed
western blot analysis in fibroblast extracts of 14 cell
lines. SDS-PAGE, followed by western blot analysis, re-
peatedly showed very small amounts of a normal-sized
63-kD CBS in fibroblasts derived from patient 1; none
of the other 13 cell lines contained detectable CBS sub-
units (data not shown). A more sensitive nondenaturing
PAGE, followed by western blot analysis, was used to
determine the degree of assembly of CBS subunits that
are responsible for the observed residual enzyme activity.
Cell lysates of cultured skin fibroblasts were prepared
from frozen pellets, using the PEE-W1 lysis buffer (Kraus
1987). For western blot analysis, 10–100 mg of total
protein was electrophoresed on 7.5% native polyacryl-
amide gel at 5 V/cm, followed by a transfer onto poly-
vinylidene difluoride membrane (Immobilon-P, Milli-
pore). CBS subunits were detected by use of anti-CBS
antibody (dilution 1:2,000 in 3% BSA in 1#PBS), fol-
lowed by secondary anti-rabbit IgG conjugated with
horseradish peroxidase (Jackson ImmunoResearch) di-
luted 1:30,000 in 5% nonfat dry milk dissolved in
1#PBS with 0.2% Tween 20, and they were visualized
with the ECL detection kit (Amersham Pharmacia Bio-
tech) and fluorography with XOmat AR film (Kodak).
The slowly migrating complexes are marked as aggre-
gates. Figure 2 (a representative example of three re-
peated determinations) shows that none of the mutant
cell lines contained any detectable amount of the CBS
tetramer. The majority of mutant fibroblast extracts con-
tained minute amounts of large immunoreactive com-
plexes that were slow to emerge from the loading well
and slow to migrate on the gel. In normal fibroblasts,
these multimeric aggregates have been observed in small
amounts in repeatedly frozen and thawed samples (see
fig. 2, lane C1) but not in freshly prepared extracts (fig.
2, lane C2). The aggregates are indeed formed by CBS
polypeptides—as demonstrated by their absence in ex-
tracts from cell line 599 (fig. 2, lane N), which had been
previously shown to be devoid of any CBS antigen (Sko-
vby et al. 1984). The data from western blotting under
nondenaturing conditions suggest that (1) the steady-
state amounts of CBS polypeptides produced from 10
distinct mutant alleles are severely decreased in vivo, (2)
the mutants do not form tetramers, and (3) the mutants
aggregate.
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Table 2
Description of Patients
PATIENT
NUMBERa ORIGINb SEX
CURRENT
AGE
(YEARS)
PYRIDOXINE
RESPONSEc
GENOTYPE
CBS
ACTIVITYdAllele 1 Allele 2
1 CZ F 6  c.494 GrA c.494 GrA .46
2 CZ M 11  IVS112 ArC [c.430 GrA; c.463 GrA] .00
3 SK F 14  c.19_20insC c.19_20insC .46
4 CZ M 15  IVS112 ArC [IVS71GrA; IVS1139del99] .00
5 SK F 16  Unknown Unknown NA
6 SK M 19  IVS112 ArC c.1226 GrA .10
7 SK M 20  c.526 GrA c.526 GrA .03
8* CZ M 20  IVS11GrC c.28_29delG NA
9 SK F 21  IVS112ArC c.19_20insC .33
10* CZ M 22e  IVS11GrC c.28_29delG .03
11 CZ M 33  c.194 ArG Unknown .02
12 SK M 19  IVS112 ArC Unknown NA
13† SK M 24  IVS112 ArC c.833 TrC .03
14 CZ M 25  Unknown Unknown NA
15† SK F 25  IVS112 ArC c.833 TrC .00
16‡ CZ M 15  c.833 TrC [c.430 GrA; c.463 GrA] NA
17‡ CZ F 17  c.833 TrC [c.430 GrA; c.463 GrA] .10
18 CZ M 21  c.341 CrT c.1226 GrA .13
19 CZ F 26  c.833 TrC IVS112 ArC .05
20 CZ M 33  c.833 TrC c.833 TrC .23
21 CZ M 47  c.833 TrC c.833 TrC .43
a Asterisks (*), daggers (†), and double daggers (‡) indicate sib pairs.
b CZ p Czech; SK p Slovak.
c  p positive response;  p partial response;  p no response.
d CBS activity in cultured skin fibroblasts expressed in nanomoles of cystathionine per milligram of total protein per hour.
Control range 10–40 nmol/mg/h. NA p not applicable.
e Patient 10 died at the age of 22 years because of pulmonary embolism.
To verify the hypothesis that the mutant CBS subunits
are misfolded and aggregated, we also expressed five
mutations in E. coli and performed western blot analysis
under denaturing and native conditions. The procedure
was the same as that in figure 2, with the following
modifications: lysates from E. coli cell pellets were pre-
pared using sonication in potassium phosphate buffer,
samples were tested on 9% SDS-PAGE, and affinity-
purified CBS antibody was used (Kozich and Kraus
1992). The size and abundance of mutant subunits ex-
pressed in E. coli were compared with those of the wild-
type enzyme; the wild-type human CBS has the calcu-
lated and apparent molecular weight of 60.6 kD and 63
kD, respectively; the shorter band, with deletion of exon
12, has a calculated molecular weight of 55.6 kD. In
contrast to human fibroblasts, the A114V (c.341CrT),
A155T (c.463GrA), and E176K (c.526GrA) mutants
were easily detectable on SDS-PAGE (see fig. 3) in
amounts comparable to those in the wild type, a result
that demonstrated their stability in E. coli extracts. The
steady-state amounts of the I278T (c.833CrT) and of
the W409_G453del (IVS112ArC) mutants are de-
creased, compared with wild type and with the other
three mutants, a result that suggests a decreased stability
in the bacterial expression system.
Analysis of crude extracts from bacteria under na-
tive conditions was performed to confirm the obser-
vations made in fibroblast extracts. The procedure
was the same as that shown in figure 3, with the ex-
ception of the use of nondenaturing 9% PAGE. West-
ern blot analysis using CBS-specific antibody showed
that, under native conditions, the wild-type CBS pro-
tein in the crude extract is present in its normal tet-
rameric form and that a small portion of the wild-type
enzyme also forms multimers. In contrast, all five CBS
mutants are present in the crude extract, almost exclu-
sively as aggregates with high molecular weights (fig. 4,
left). A small amount of a tetramer was detected only
in the case of the A114V (c.341CrT) mutant, a result
consistent with the mutant’s high residual activity, and
traces of tetramer were observed in E176K (c.526GrA)
at the detection limit of the procedure.
To limit the possibility that aggregates form as an
artifact in vitro, we always repeated the nondenaturing
western blot analyses at least twice with freshly prepared
fibroblast and bacterial extracts, and, on several occa-
sions, we added b-mercaptoethanol and protease inhib-
itors. These repeated experiments (data not shown)
yielded identical results that were indistinguishable from
those shown in figures 2 and 4. The ability to detect
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consistently the normally assembled tetramer in control
samples and the presence of aggregates in mutant sam-
ples suggest that the in vitro data reflect reasonably well
the subunit assembly within cells and are not artifacts.
We have reported elsewhere that heme may be nec-
essary for binding of pyridoxal 5′-phosphate to CBS
(Kery et al. 1994), and we postulated that heme may be
necessary for correct CBS folding (Kery et al. 1999). We
have also reported that the G307S (c.919GrA) mutant
expressed in E. coli does not contain heme (Kery et al.
1995). These data suggest that heme may play a role in
mutant subunit assembly. We therefore analyzed the
heme content in five mutants expressed in E. coli. Bac-
terial crude extracts from both mutant and wild-type
cells were electrophoresed under native conditions, and
western blot gels were stained and examined for the
presence of heme (Vargas et al. 1993). The experiments
demonstrated that only the tetramers of wild-type cell
or the A114V (c.341CrT) mutant contain heme, but
aggregates of both mutant and wild-type CBS are devoid
of this ligand (see fig. 4, right panel). This observation
suggests that the inability to bind heme may prevent
correct folding and subsequent tetramer formation of
both mutant and, to a lesser extent, normal CBS sub-
units. Conversely, it may be the inability to retain the
heme molecule that makes the mutants prone to mis-
folding and aggregation. Further studies are needed to
explore each of these possibilities.
To conclude, we hypothesize that the abnormal fold-
ing of mutant CBS that is associated with impaired heme
binding alters tertiary structure and exposes hydropho-
bic domains, most likely in the COOH terminal region.
The abnormally folded molecules may be either forced
to degradation by proteasome (Kirschner 1999) or may
form aggregates. In human cells, these aggregates may
be sequestered into aggresomes (Johnston et al. 1998),
which are resistant to proteolytic degradation. The net
result of these processes within the cells thus may be
severe depletion of the abnormally assembled polypep-
tide complexes, as well as of mutant tetramers. We pos-
tulate that, as with other genetic defects (Bross et al.
1999), mutant CBS misfolding and aggregation may be
the primary defect in a significant proportion of patients
with homocystinuria.
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